We’re weaving innovation into the fabric of everything we do
Specialized and routine testing
Routine lab testing, particularly if deferred during the pandemic, is an important tool for developing a baseline understanding of your patient’s ongoing health. We offer a full portfolio of baseline/routine lab testing and annual screenings to help urgent care centers facilitate physicals and identify patients who may need additional testing or follow-up care for new conditions that may have gone undetected due to deferred care during the pandemic.
Cardiovascular disease remains the leading cause of death in the US.1 We’re helping urgent care centers shine a light on patients at increased risk for cardiometabolic diseases and improve clinical outcomes through early identification and intervention in patients with heart disease and metabolic-associated conditions.
Learn more about our innovative test solutions for cardiovascular disease
Delivering care throughout a woman’s life requires testing and support that you can rely on to provide insights at the times when patients and their families need them the most.
Quest Advanced® Women’s Health is making advanced and specialty testing more actionable and accessible to support you and your patients.
See how our tests, services, and expertise can make a difference in patient care
Our powerful combination of responsive turnaround and specialized technologies for advanced immunology and infectious disease testing helps inform and empower earlier interventions.
Learn more about our diverse and innovative IDI test portfolio
With a broad selection of tests, fast turnaround time, and enhanced, easy-to-read results via medMATCH® reporting, we can help you efficiently make informed care decisions. Whether you are starting a drug monitoring program, or looking to complement your existing services, see why healthcare professionals trust Quest to be their lab of choice for clinical drug monitoring.
Learn more about our comprehensive services for drug testing
Clinicians see many patients, male and female, with a wide range of testing needs. Our comprehensive menu provides the tests you need to diagnose patients who present with symptoms, and to catch asymptomatic infections in those who don’t. We help you deliver the highest quality of care, from testing through follow-up.
Routine lab testing, particularly if deferred during the pandemic, is an important tool for developing a baseline understanding of your patient’s ongoing health. We offer a full portfolio of baseline/routine lab testing and annual screenings to help urgent care centers facilitate physicals and identify patients who may need additional testing or follow-up care for new conditions that may have gone undetected due to deferred care during the pandemic.
Cardiovascular disease remains the leading cause of death in the US.1 We’re helping urgent care centers shine a light on patients at increased risk for cardiometabolic diseases and improve clinical outcomes through early identification and intervention in patients with heart disease and metabolic-associated conditions.
Learn more about our innovative test solutions for cardiovascular disease
Delivering care throughout a woman’s life requires testing and support that you can rely on to provide insights at the times when patients and their families need them the most.
Quest Advanced® Women’s Health is making advanced and specialty testing more actionable and accessible to support you and your patients.
See how our tests, services, and expertise can make a difference in patient care
Our powerful combination of responsive turnaround and specialized technologies for advanced immunology and infectious disease testing helps inform and empower earlier interventions.
Learn more about our diverse and innovative IDI test portfolio
With a broad selection of tests, fast turnaround time, and enhanced, easy-to-read results via medMATCH® reporting, we can help you efficiently make informed care decisions. Whether you are starting a drug monitoring program, or looking to complement your existing services, see why healthcare professionals trust Quest to be their lab of choice for clinical drug monitoring.
Learn more about our comprehensive services for drug testing
Clinicians see many patients, male and female, with a wide range of testing needs. Our comprehensive menu provides the tests you need to diagnose patients who present with symptoms, and to catch asymptomatic infections in those who don’t. We help you deliver the highest quality of care, from testing through follow-up.
Innovative solutions that help you do more for your patients
|
Quest UrgentDx reference guide is a curated menu of tests commonly ordered in urgent care centers through Quest—making it easier to order the tests you need, when you need them. Specialty test areas include: general health and wellness, cardiometabolic disorders and heart health, women’s health, infectious disease and immunology, clinical drug monitoring, and sexually transmitted infections |
|
|
|
|
Our industry-leading operations and capabilities across our nationwide network of labs allow us to meet surging demands and deliver actionable insights to 160 million patients each year |
|
|
|
|
COVID-19 tests for evolving needs with active infection, rapid antigen, antibody, and a range of respiratory pathogen co-testing panels |
|
|
|
|
Telehealth service support for lab test ordering for virtual care visits |
|
|
|
|
On-hold ordering—communications with patients and providers |
Better outcomes with support for your patients throughout their healthcare journeys
|
Confirmatory testing for initial rapid results so you can initiate the right treatment plan |
|
|
|
|
STAT testing services available for send-outs and fast turnaround, so you can make informed care decisions quickly |
|
|
|
|
Access to 3,500 routine and esoteric tests for nearly every health condition |
|
|
|
|
Low to no out-of-pocket costs for many of the 160 million patients we serve annually |
|
|
|
|
Our medical team is here for your team—we have 650+ MDs and PhDs available for consultation on test selection and results interpretation |
- American Heart Association. CDC prevention programs. Updated May 18, 2018. Accessed May 3, 2022. https://www.heart.org/en/get-involved/advocate/federal-priorities/cdc-prevention-programs
- The antibody tests have not been FDA cleared or approved
- The antibody tests have been authorized by FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories
- The antibody tests have been authorized only for detecting antibodies against SARS-CoV-2, not for any other viruses or pathogens
- The SARS-CoV-2 Total Antibody, Spike, Semi-Quantitative test has been authorized by FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform high complexity tests
- The IgM serology test component has been authorized only for the detection of IgM antibodies against SARS-CoV-2, not for any other viruses or pathogens
- These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner
- The Cepheid SARS-CoV-2, Influenza A/B and RSV test, the cobas® SARS-CoV-2 & Influenza A/B Test and the Quest SARS-CoV-2 RT-PCR test and other molecular tests (“Tests”) have not been FDA cleared or approved.
- The Roche® test has been authorized only for the detection of RNA from SARS-CoV-2 virus, Influenza A virus, and Influenza B virus and not any other viruses or pathogens.
- The Cepheid SARS-CoV-2, Influenza A/B and RSV test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens;
- The Cepheid SARS-CoV-2, Influenza A/B and RSV test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
- The Roche test is only authorized for the duration of the declaration that circumstances exist justifying the authorized of the emergency use of in vitro diagnostics for detection and differentiation of SARS-CoV-2 virus, Influenza A, and Influenza B under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorized is terminated or revoked sooner.
- The Tests have been authorized by the FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests.
- The Quest test and other molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens.
- The Quest test and other molecular tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
- The COVID-19 antigen test has not been FDA cleared or approved;
- This test has been authorized by FDA under an EUA for use by authorized laboratories;
- This test has been authorized only for the detection of proteins from SARS-CoV-2, and not for any other viruses or pathogens; and
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
